(316 days)
Not Found
Indirect Immunofluorescence (IFA) or Immunoperoxidase (IIP)
No
The device description details a standard enzyme immunoassay (ELISA) dot blot technique, which is a traditional laboratory method and does not involve AI or ML. There are no mentions of AI, ML, or image processing in the summary.
No
This device is an in vitro diagnostic test for detecting antibodies to diagnose scrub typhus, not a therapeutic device.
Yes
The "Intended Use / Indications for Use" section explicitly states that the device "is an enzyme immunoassay for use as an aid in the diagnosis of scrub typhus."
No
The device description clearly outlines a physical enzyme immunoassay kit with assay strips, reaction vessels, and reagents, indicating it is a hardware-based diagnostic test, not software only.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use explicitly states it is "for use as an aid in the diagnosis of scrub typhus" and "detects total IgG and IgM antibodies to Orientia tsursugamushi." This clearly indicates it is used to examine specimens from the human body to provide information for diagnostic purposes.
- Device Description: The description details an "enzyme immunoassay" and "ELISA dotblot technique" which are common methods used in in vitro diagnostic testing to detect specific substances (in this case, antibodies) in biological samples.
- Specimen Type: The test is intended for use with "serum as well as heparinized plasma, whole blood and finger-stick capillary blood," all of which are biological specimens taken from the human body.
- Performance Studies: The inclusion of performance studies comparing the device to predicate methods (IFA and IIP) and reporting metrics like sensitivity, specificity, and agreement are standard for demonstrating the analytical and clinical performance of an IVD.
The definition of an In Vitro Diagnostic (IVD) is a medical device that is used to perform tests on specimens taken from the human body, such as blood, urine, or tissue, to provide information for the diagnosis, monitoring, or treatment of a disease or condition. The INDX Dip-S-Ticks scrub typhus test fits this definition perfectly.
N/A
Intended Use / Indications for Use
The INDX® DIP-S-TICKS® Scrub Typhus Test For the Detection of IgG and IgM Antibodies to Orientia tsutsugamushi (scrub typhus) is a semi-quantitative enzyme immunoassay for the detection of total IgG and IgM antibodies to Orientia tsutsugamushi, for the serological confirmation of scrub typhus in samples of serum, plasma or heparinized whole blood. This test is intended to be performed by trained medical technologists only.
The INDX" Dip-S-Ticks scrub typhus test is an enzyme immunoassay for use as an aid in the diagnosis of scrub typhus, and detects total IgG and IgM antibodies to Orientia tsursugamushi. The Dip-S-Ticks test is qualitative when used to test a single specimen; when using paired specimens to detect sero-conversion the test may be semi-quantitative. The test is intended for use in serum as well as heparinized plasma, whole blood and finger-stick capillary blood and is intended to be performed by trained medical personnel only.
Product codes (comma separated list FDA assigned to the subject device)
LSO
Device Description
The INDX® DIP-S-TICKS® Scrub Typhus Test For the Detection of IgG and IgM Antibodies to Orientia tsutsugamushi (scrub typhus) utilizes an enzyme-linked immunoassay (ELISA) dotblot technique for the detection of IgM as well as total (IgM and IgG) dengue antibodies. The antigen is dispensed as discrete dots onto a solid membrane. After adding specimen to a reaction vessel, an assay strip is inserted, allowing patient antibodies reactive with the test antigen to bind to the strip's solid support membrane. In the second stage, the reaction is enhanced by removal of non-specifically bound materials. During the third stage, alkaline phosphatase-conjugated anti-human IgG/IgM antibodies are allowed to react with bound patient antibodies. Finally, the strip is transferred to enzyme substrate reagent, which reacts with bound alkaline phosphatase to produce an easily seen, distinct spot.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
trained medical technologists only.
trained medical personnel only.
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Comparison Studies
Study No. 1 Comparison of Methods On 91 Febrile Sera from NorthCentral Malaysia
Study type: Comparison
Sample size: 91
Source: All samples were obtained from a U.S. medical reference laboratory for rickettsial diseases. The samples were acquired retrospectively from 56 clinical cases of febrile patients in North Central peninsular Malaysia.
Performance Characteristics: SENSITIVITY = 90.4%, SPECIFICITY = 66.7%, AGREEMENT = 80.2%
Results of Semi-Quantitative Comparisons: The semi-quantitative relationship between the number of positive Karp strain O. tsutsugamushi DIP-S-TICKS dots and the inverse of geometric means of IFA titers was determined. As the table indicates, the inverse of geometric mean titers for IgM and for IgG consistently increased as the number of positive dots increased.
Study No. 2: Comparison of Methods On Sera From 60 Febrile Patients from Northern Thailand
Study type: Comparison
Sample size: 60
Source: Samples of 60 sera from febrile patients were obtained prospectively from the Chiangrai Hospital in Thailand.
Performance Characteristics: SENSITIVITY = 100.0%, SPECIFICITY = 95.5%, AGREEMENT = 96.7%
Study No. 3: Comparison of Methods On Sera From 83 Febrile Patients from North-East Thailand
Study type: Comparison
Sample size: 83
Source: Sera samples from 83 febrile patients were obtained at the Mahara Hospital in Nakhon Ratchasima province of North-East Thailand. This prospective study was conducted between November, 1995 and January, 1996.
Performance Characteristics: SENSITIVITY = 86.7%, SPECIFICITY = 94.3%, AGREEMENT = 91.6%
Study No. 4: Comparison of Methods On 28 Paired Acute and Convalescent Sera from NorthCentral Malaysia
Study type: Comparison
Sample size: 28 paired acute and convalescent sera
Source: An extension of study No. 1.
Performance Characteristics: SENSITIVITY = 88.5%, SPECIFICITY = 100.0%, AGREEMENT = 89.3%
Overall Comparison of Methods across the four studies:
Mean Sensitivity: 91.4%
Mean Specificity: 89.1%
Mean Agreement: 89.5%
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Overall Mean Sensitivity: 91.4%
Overall Mean Specificity: 89.1%
Overall Mean Agreement: 89.5%
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
INDX Indirect Immunofluorescence (IFA) Slide Test for the Detection of Antibodies to Rickettsial Species (O. tsutsugamushi).
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Indirect Immunofluorescence (IFA) or Immunoperoxidase (IIP)
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 866.3500 Rickettsia serological reagents.
(a)
Identification. Rickettsia serological reagents are devices that consist of antigens and antisera used in serological tests to identify antibodies to rickettsia in serum. Additionally, some of these reagents consist of rickettsial antisera conjugated with a fluorescent dye (immunofluorescent reagents) used to identify rickettsia directly from clinical specimens. The identification aids in the diagnosis of diseases caused by virus-like bacteria belonging to the genusRickettsiae and provides epidemiological information on these diseases. Rickettsia are generally transmitted by arthropods (e.g., ticks and mosquitoes) and produce infections in humans characterized by rash and fever (e.g., typhus fever, spotted fever, Q fever, and trench fever).(b)
Classification. Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 866.9.
0
Image /page/0/Picture/0 description: The image shows the logo for Integrated Diagnostics, Inc. The logo features the letters "IDx" stacked on top of each other in a stylized font. The letters are made up of horizontal lines that get progressively shorter as they move away from the letters. The company name, "INTEGRATED DIAGNOSTICS, INC.", is printed in bold, all-caps letters below the logo.
MAR 13 1998
- 海 . .
510(K) SUMMARY SUMMARY OF SAFETY AND EFFECTIVENESS DATA
INDX® DIP-S-TICKSR Scrub Typhus Test For the Detection of IgG and IgM Antibodies to Orientia tsutsugamushi (scrub typhus)
NAME AND LOCATION OF MANUFACTURER:
Integrated Diagnostics, Inc. (INDX) 1756 Sulphur Spring Road Baltimore, MD 21227 Phone (410) 737-8500 FAX (410) 536-1212
NAME OF CONTACT PERSON:
Helene Paxton, M.A., M.T. (ASCP) President Integrated Diagnostics, Inc.
DATE OF PREPARATION OF SUMMARY:
April 30, 1997
1
TRADE NAME OF THE DEVICE:
INDX® DIP-S-TICKS* Scrub Typhus Test For the Detection of IgG and IgM Antibodies to Orientia tsutsugamushi (scrub typhus)
COMMON NAME:
DIP-S-TICKS& Scrub Typhus Test
CLASSIFICATION NAME:
Rickettsia serological reagents, 21 CFR 866.3500
LEGALLY MARKETED DEVICE (PREDICATE DEVICE) TO WHICH THE MANUFACTURER IS CLAIMING SUBSTANTIAL EQUIVALENCE:
INDX Indirect Immunofluorescence (IFA) Slide Test for the Detection of Antibodies to Rickettsial Species (O. tsutsugamushi). In this notification, comparisons were also made to the Indirect Immunoperoxidase (IIP) method, which is identical to the IFA test, except for the use of a fluorescence rather than an enzyme-conjugated substrate on a prepared slide. The IIP method enables the use of a light microscope for antibody detection rather than a fluorescence microscope.
DESCRIPTION OF THE DEVICE:
The INDX® DIP-S-TICKS® Scrub Typhus Test For the Detection of IgG and IgM Antibodies to Orientia tsutsugamushi (scrub typhus) utilizes an enzyme-linked immunoassay (ELISA) dotblot technique for the detection of IgM as well as total (IgM and IgG) dengue antibodies. The antigen is dispensed as discrete dots onto a solid membrane. After adding specimen to a reaction vessel, an assay strip is inserted, allowing patient antibodies reactive with the test antigen to bind to the strip's solid support membrane. In the second stage, the reaction is enhanced by removal of non-specifically bound materials. During the third stage, alkaline phosphatase-conjugated anti-human IgG/IgM antibodies are allowed to react with bound patient antibodies. Finally, the strip is transferred to enzyme substrate reagent, which reacts with bound alkaline phosphatase to produce an easily seen, distinct spot.
INTENDED USE OF THE DEVICE:
The INDX DIP-S-TICKS® Scrub Typhus Test For the Detection of IgG and IgM Antibodies to Orientia tsutsugamushi (scrub typhus) is a semi-quantitative enzyme immunoassay for the detection of total IgG and IgM antibodies to Orientia tsutsugamushi, for the serological confirmation of scrub typhus in samples of serum, plasma or heparinized whole blood. This test is intended to be performed by trained medical technologists only.
2
SUMMARY OF THE TECHNICAL CHARACTERISTICS OF THE MANUFACTURER'S DEVICE COMPARED TO THE PREDICATE DEVICE:
| No. | Item
Comparison | INDX Device | Reference Device(s) | Comparison |
|-----|-----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------|-----------------------------|
| 1. | Intended Use | Detection of scrub
typhus antibody | Detection of scrub
typhus antibody | Substantially
equivalent |
| 2. | Agent Measured | O. tsutsugamushi | O. tsutsugamushi | Substantially
equivalent |
| 3. | Disease and phase
of disease | Scrub typhus, acute
and convalescent
phases | Scrub typhus, acute
and convalescent
phases | Substantially
equivalent |
| 4. | Specificity | IgG and IgM
Antibody to
Agent | IgG and IgM
Antibody to
Agent | Substantially
equivalent |
| 5. | Format | EIA dot-blot | Indirect
Immunofluorescence (IFA)
or Immunoperoxidase (IIP) | Substantially
equivalent |
| 6. | Endpoint detection
method | Enzyme-substrate
and conjugate in a
solid phase | Enzyme-substrate
or fluorescent substrate
on a prepared slide | Substantially
equivalent |
| 7. | Use of results | Semi-quantitative | Semi-quantitative | Substantially
equivalent |
| 8. | Sample prep.
methods | heparinized serum
plasma or
whole blood | serum | Substantially
equivalent |
| 9. | Positive and
Negative Controls | Required and
Included | Required and
Included | Substantially
equivalent |
| 10. | Summary of
Comparisons | Average Sensitivity for Comparisons of 91.4%
Average Specificity for Comparisons of 89.1%
Average Agreement for Comparisons of 89.5% | | Substantially
equivalent |
COMPARISONS OF INDX DIP-S-TICKS AND REFERENCE METHODS
3
NON-CLINICAL TESTS SUPPORTING A DETERMINATION OF SUBSTANTIAL EQUIVALENCE:
Expected Values
The number of antibody positive subjects in a population depends on two factors: disease prevalence and clinical criteria used to select the tested population. Because very few positives should be seen in a randomly screened population in a non-endemic area, most serology tests are not specific enough to screen non-endemic populations. Even in an endemic region, serology screening often yields many false positives if used to randomly screen patients. Serology tests are useful to test patients in an endemic region with signs and symptoms consistent with the disease.
Antibody levels are generally low or absent during very early infection. Symptomatic patients may have no antibody during the first 1-2 weeks after exposure and the antibody titer will rise with time.
Normal Population
Sera obtained from a total of ten (10) asymptomatic normal donors were evaluated with the DIP-S-TICKS method in this study. All sera had a negative IFA result for scrub typhus and were subsequently evaluated by the dot-blot method. All of 10 sera were negative or non-reactive to the dot-blot method.
Negative Patient Control Sera: (Presumptive Negatives)
The following table summarizes the results of the study, and indicates the types of nonrickettsial diseases, number of sera evaluated for each disease, and results of the DIP-S-TICKS dot-blot test for scrub typhus. In this study, the DIP-S-TICKS test showed a negative result in 49 of 51 sera that were confirmed not to have scrub typhus, and was positive in 2 of the 51 sera. Only one of the positive samples (malaria) is a tropical disease that might be encountered in the same geographic environment as scrub typhus.
| DISEASE | NUMBER OF
SERA TESTED | DIP-S-TICKS
NEGATIVE | DIP-S-TICK
POSITIVE |
|----------------------|--------------------------|-------------------------|------------------------|
| Rheumatoid Factor | 10 | 9 | 1 |
| Antinuclear Antibody | 11 | 11 | 0 |
| Malaria | 6 | 5 | 1 |
| Bartonellosis | 6 | 6 | 0 |
| Leptospirosis | 6 | 6 | 0 |
| Typhoid | 3 | 3 | 0 |
| Cholera | 9 | 9 | 0 |
| TOTAL | 51 | 49 | 2 |
4
Precision Study:
The Kato/Gilliam antigen is included in the DIP-S-TICKS test strip at a screening dilution and is scored as either positive. In precision studies, reactions were graded as 0 dot (negative), 0.5 dots (equivocal) and 1 dot (positive). Replicate tests conducted within the same day using standard non-immune sera consistently resulted in 0 dot (negative) reaction. The following data are representative of studies of replicate test strips conducted within the same day with the indicated Kato/Gilliam positive human immune sera. Sera listed more than once represent the evaluation of strips on separate days.
| Sera No. | Mean
Response
(No. of dots) | S.D. | Range | n |
|----------|-----------------------------------|-----------|---------|----|
| S0023 | 0.6 | $\pm$ 0.2 | 0.5-1.0 | 11 |
| S0023 | 0.6 | $\pm$ 0.2 | 0.5-1.0 | 11 |
| S0024 | 0.8 | $\pm$ 0.2 | 0.5-1.0 | 11 |
| S0024 | 1.0 | $\pm$ 0.0 | 1.0-1.0 | 9 |
| S0025 | 1.0 | $\pm$ 0.0 | 1.0-1.0 | 15 |
| HAS | 1.0 | $\pm$ 0.0 | 1.0-1.0 | 15 |
The Karp antigen is included in the DIP-S-TICKS test strip at 3 dilutions in the range of 1:400 to 1:6400 or greater. This range of Karo antigen is intended to permit an assessment of the relative O. tsutsugamushi antibody strength to which the Karp antigen reacts. The antibody strength is indicated by the number of positive Karp antigen dots observed. In precision studies, replicate tests conducted within the same day using standard non-immune sera consistently resulted in 0 dot (negative) reaction. The following data are representative of studies of replicate test strips conducted within the same day with the indicated Karp positive human immune sera. Sera listed more than once represent the evaluation of strips on separate days.
| Sera No. | Mean
Response
(No. of dots) | S.D. | Range | n |
|----------|-----------------------------------|-----------|---------|----|
| S0023 | 2.5 | $\pm$ 0.0 | 2.5-2.5 | 11 |
| S0023 | 2.6 | $\pm$ 0.2 | 2.5-3.0 | 11 |
| S0023 | 3.0 | $\pm$ 0.0 | 3.0-3.0 | 9 |
| S0024 | 2.5 | $\pm$ 0.0 | 2.5-2.5 | 9 |
| S0024 | 2.3 | $\pm$ 0.2 | 2.0-2.5 | 11 |
| HAS | 2.5 | $\pm$ 0.1 | 2.0-2.5 | 15 |
5
CLINICAL TESTS SUPPORTING A DETERMINATION OF SUBSTANTIAL EQUIVALENCE:
Comparison Studies
Study No. 1 Comparison of Methods On 91 Febrile Sera from NorthCentral Malaysia
A group of 91 presumptive positive samples were tested. All samples were obtained from a U.S. medical reference laboratory for rickettsial diseases. The samples were acquired retrospectively from 56 clinical cases of febrile patients in North Central peninsular Malaysia.
The 91 presumptive positive samples were analyzed for the presence of scrub typhus antibodies by the DIP-S-TICKS Dot-Blot and indirect immunofluorescence (IFA) methods. Both methods detect the presence of IgM and IgG antibodies.
Performance Characteristics for 91 febrile samples:
SENSITIVITY = 90.4% SPECIFICITY = 66.7% AGREEMENT = 80.2%
Results of Semi-Quantitative Comparisons for 91 febrile samples:
The semi-quantitative relationship between the number of positive Karp strain O. tsutsugamushi DIP-S-TICKS dots and the inverse of geometric means of IFA titers was determined for the group of 91 febrile sera. For the IFA method, the IgG and IzM scrub typhus titers are reported separately. The DIP-S-TICKS method detected total (IgG and IgM) scrub typhus antibodies. These data are shown in the following table. As the table indicates, the inverse of geometric mean titers for IgM and for IgG consistently increased as the number of positive dots increased. However, the range of IFA IgG titers is much larger than the range of IFA IgM titers and better discrimination between IgG titers is possible when comparing to the corresponding number of DIP-S-TICKS dots. The differences shown were statistically significant between 0, 1 and 2 or 3 dots for IgG. The differences shown were statistically significant between 0 and 3 dots for IgM.
6
Geometric means of inverse indirect immunofluorescence (IFA) titers for each level of DIP-S-TICKS response using the Karp strain of O. tsutsugamushi antigen in tests of 91 clinical sera
| No. of Positive
| dots on the | Inverse of Geometric Mean IFA Titer | |
|---|---|---|
| DIP-S-TICKS | IgG | IgM |
| 0 | 6.1 † | 2.3 † |
| 1 | 26.5 † | 3.5 †‡ |
| 2 | 183.8 ‡ | 4.1 †‡ |
| 3 | 98.0 ‡ | 9.7 ‡ |
Means in a column not followed by the same symbol were significantly different (P 3 dots denotes a 4-fold increase, since the O. tsutsugamushi antigen is diluted 4 fold for each antigen dot.
Performance Characteristics of the DIP-S-TICKS test compared to the IFA test for 28 paired sera samples:
| SENSITIVITY = | 88.5% |
|---|---|
| SPECIFICITY = | 100.0% |
| AGREEMENT = | 89.3% |
In summary, four independent studies of the comparison of the DIP-S-TICKS and either the IFA or IIP predicate methods were conducted on a total of 262 sera samples from febrile patients. In these studies, either single samples (3 studies and 234 sera) or paired acute and convalescent samples (1 study and 28 sera) formed the basis for comparison. The overall comparison of methods was as follows:
8
| STUDY | SENSITIVITY | SPECIFICITY | AGREEMENT
BETWEEN
METHODS | n |
|----------|-------------|-------------|---------------------------------|----|
| No. 1 | 90.4 | 66.7 | 80.2 | 91 |
| No. 2 | 100.0 | 95.5 | 96.7 | 60 |
| No. 3 | 86.7 | 94.3 | 91.6 | 83 |
| No. 4 | 88.5 | 100.0 | 89.3 | 28 |
| Mean | 91.4 | 89.1 | 89.5 | |
| ± 1 S.D. | 5.9 | 15.2 | 6.9 | |
BIBLIOGRAPHY
- Elisberg, BL and FM Bozeman, The Rickettsiae. in Diagnostic Procedures for Viral, Rickettsial and 1. Chlamydial Infections, 5th Ed. Eds. EH Lennetts & NJ Schmidt, pp 1061-1099, 1979.
- Centers for Disease Control, 1981. Rickettsial Surveillance Report No. 2. Summary: 1979. U.S. 2. Department of Health and Human Services, Washington, D.C.
- Fiset, P. "Clinical Laboratory Diagnosis of Rickettsial Disease of Man" in Handbook of Clinical Laboratory 3. Science, Vol. 1, Part 2, Hsuing, G.D. and Green, R.H. Eds., CRC Press, West Palm Beach, Florida, p361-366, 1978.
- Centers for Disease Control/National Institutes of Health Manual Biosafety in Microbiological and 4. Biomedical Laboratories, 1984.
- Brown G.W., Scrub typhus: pathogenesis and clinical syndrome, In Walker D.H., (ed), Biology of રું છે. Rickettsial Diseases, Vol. 1, p. 93-100, CRC Press, Inc. Boca Raton, 1988.
- Strickman D., Serology of scrub typhus: New directions for an old disease, Clin. Immunol. Newsletter 6. 14:(5)62-65, 1994.
-
- Strickman D., Tanskul P., Eamsila C. et al, Prevalence of antibodies to rickettsiae in the human population of suburban Bangkok, Am. J. Trop. Med. Hyg. 51:149-153, 1994.
-
- Brown G.W., Shirai A., Rogers C. et al, Diagnostic criteria for scrub typhus: Probability values for immunofluorescent antibody and Proteus OXK agglutinin titers, Am. J. Trop. Med. Hyg. 32(5):1101-1107, 1983.
- Weddle J.R., Chan T.C., Thompson K. et al, Effectiveness of a dot-blot immunoassay of anni-Rickettsia 9. tsutsugamushi antibodies for serological analysis of scrub typhus, Am. J. Trop. Med. Hyg. 53(1):43-46, 1995.
-
- Chouriyagune C., Watt G., Strickman D., Jinasen R., The Weil-Felix test for the diagnosis of scrub typhus in Thailand. Intern. Med. 8:29-32. 1992.
-
- Kelly D.J., Serologic diagnosis of rickettsial diseases, Clin. Immunol. Newsletter 14:57-61, 1994.
- Kelly D.J., Wong P.W., Gan E. et al. Multi-laboratory evaluation of a scrub typhus diagnostic kit. Am. 12. J. Trop. Med. Hyg. 43:301-307. 1990.
- McDade J.E., Fishbein D.B., Rickettsiaceae: the rickettsiae, In E.H. Lennette, P. Halonen, F.A. Murphy 13. (Eds.), Laboratory diagnosis of infectious diseases, Principles and practice, Vol II, p. 864-890, New York, Springer-Verlag, 1988.
- Wisseman C.L., Scrub typhus, In Strickland, G.T. (ed.) Hunter's Tropical Medicine (6th Edition), p. 221-14. 223, Philadelphia, W.B. Saunders, 1991.
9
Image /page/9/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized eagle with three stripes forming its body and wing. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" are arranged in a circular pattern around the eagle.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
MAR 1 3 1998
Integrated Diagnostics, Inc. c/o David C. Bishop, Ph.D. Consultant to INDX 605 Dilworth Road Downingtown, PA 19335
Re: K971591 Trade Name: INDX Dip-S-Ticks Scrub Typhus Test Regulatory Class: I Product Code: LSO Dated: December 22, 1997 Received: December 24, 1997
Dear Dr. Bishop:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the - Current Good Manufacturing Practice requirements: as set forth in the Ouality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
10
Page 2
Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770)488-7655.
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll free number (800) 638-2041 or at (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html"
Sincerely yours.
Steven Autman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
11
| Page | |
|---|---|
| of |
| 510(k) Number (if known): | K971591 |
|---|---|
| Device Name: | INDX Dip-S-Ticks Scrub Typhus TEST |
| Indications For Use: |
INDICATIONS FOR USE:
The INDX" Dip-S-Ticks scrub typhus test is an enzyme immunoassay for use as an aid in the diagnosis of scrub typhus, and detects total IgG and IgM antibodies to Orientia tsursugamushi. The Dip-S-Ticks test is qualitative when used to test a single specimen; when using paired specimens to detect sero-conversion the test may be semi-quantitative. The test is intended for use in serum as well as heparinized plasma, whole blood and finger-stick capillary blood and is intended to be performed by trained medical personnel only.
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Aloen
(Division Sign-Off)
Division of Clinical Laboratory Devices
510(k) Number. K97/54/
Prescription Use_ (Per 21 CFR 801.109)
OR
Over-The Counter Use__
(Optional Format 1-2-96)